Indian Journal of Surgery

, Volume 74, Issue 3, pp 210–212 | Cite as

Oophorectomy in Breast Cancer—Controversies and Current Status

Review Article

Abstract

The role of oophorectomy in the treatment of breast cancer is known for over 100 years. Ovarian ablation has a relatively large positive effect on both disease-free survival (DFS) and overall survival (OS) in premenopausal women when compared to no adjuvant treatment. Today the standard of care in adjuvant therapy of endocrine responsive tumors in premenopausal women is tamoxifen with or without chemotherapy. The role of oophorectomy /ovarian ablation in current surgical practice is discussed and important issues highlighted in the article.

Keywords

Oophorectomy Ovarian ablation Breast cancer 

References

  1. 1.
    Love RR, Philips J (2002) Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 94:1433–1434PubMedCrossRefGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681–1692CrossRefGoogle Scholar
  3. 3.
    Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  4. 4.
    Söreide JA, Varhaug JE, Fjösne HE, Erikstein B, Jacobsen A-B, Skovlund E et al (2002) Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol 28:505–510PubMedCrossRefGoogle Scholar
  5. 5.
    Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist L, Fornander T (2011) Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. Breast Cancer Res Treat 128(3):755–763PubMedCrossRefGoogle Scholar
  6. 6.
    Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M et al (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723PubMedCrossRefGoogle Scholar
  7. 7.
    Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053–2065PubMedCrossRefGoogle Scholar
  8. 8.
    Eisen A, Messersmith H, Franek J, Trudeau M, and the Breast Cancer Disease Site Group. Adjuvant ovarian ablation in treatment of premenopausal women with early stage invasive breast cancer. http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId_75982.2010
  9. 9.
    Davidson NE, O’Neill AM, Vukov AM, Osborne CK, Martino S, White DR et al (2005) Chemoendocrine therapy for premenopausal women with axillary lymph node–positive, steroid hormone receptor–positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23:5973–5982PubMedCrossRefGoogle Scholar
  10. 10.
    Griggs JJ, Somerfield MR, Anderson H, Henry NL, Hudis CA, Khatcheressian JL et al (2011) American society of clinical oncology endorsement of the cancer care ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol 29:3939–3942PubMedCrossRefGoogle Scholar

Copyright information

© Association of Surgeons of India 2012

Authors and Affiliations

  1. 1.Department of SurgeryPost Graduate Institute of Medical Education & Research, (P.G.I.M.E.R.)ChandigarhIndia

Personalised recommendations